[The influence of trans-cranial electrical stimulation on the cells of the macrophagal system of the women presenting with the climacteric syndrome]. / Vliianie transkranial'noi élektrostimuliatsii na kletki makrofagal'noi sistemy u zhenshchin s klimaktericheskim sindromom.

BACKGROUND: The search for the harmless and effective methods for the drug-free correction of various vegetovascular manifestations associated with the climacteric syndrome (CS) is currently a serious challenge facing modern medicine. Dysfunction of the ovaries during the perimenopause is characterized by the impaired production of sex steroids. The estrogens and progesterone, in their turn, are able to interact with macrophages via the specific receptors of steroid hormones localized on the surface of these cells. In this context, the trans-cranial electrical stimulation (TES) technique is of great interest due to its strong influence on the functional state of the central nervous system, subcortical brain structures, the vegetative and hormonal balance. The immunotropic effects of TES therapy described in the literature provide a basis for anticipating its beneficial action on the functional activity of monocytes/macrophages in the women presenting with the climacteric syndrome. AIM: The objective of the present study was to evaluate the influence of trans-cranial electrical stimulation on the state and stability of lysosomal membranes of blood monocytes and peritoneal macrophages, the secretory and synthetic activity of these cells in the women exhibiting the vegetovascular manifestations of the climacteric syndrome. MATERIAL AND METHODS: The influence of the transcranial electrical stimulation (TES) technique on the stability of lysosomal membranes of blood monocytes and peritoneal macrophages, the secretory and synthetic activity of these cells was studied in 23 women at the age from 45 to 52 years presenting with vegetovascular manifestations of the climacteric syndrome. The control group was comprised of 16 healthy women of the same age. The state of blood monocytes and peritoneal macrophages was evaluated before and after the course of TES therapy. To determine stability of lysosomal membranes of blood monocytes and peritoneal macrophages and calculate the stability index (PSI), the isolated cells were cultured in a medium 199 supplemented by sterile 0.5% L-glutamine and 2.5% mixed human serum previously heated at 560 °C for 30 min and at 37 °C for 12-15 hours. The micro-method was employed to determine secreted lysozyme (Lsec) as well as total lysozyme (L total=L secreted plus L intracellular) following 4-6-fold freeze-thawing of the cultured cells. The data obtained on the levels of secreted and total lysozymes were used to calculate PSI by the formula: PSI=Lsec/Ltotal´100%. The increase in PSI above the optimal value (53- 58%) was regarded as giving evidence of labilization of the lysosomal membranes and the decrease of this parameter as the indicator of membrane stabilization. Based on the difference between the total lysozyme levels before and after cultivation, the amount of newly synthesized lysozyme (L int) was determined. RESULTS: The results of the present study give evidence that the women with climacteric syndrome experience labilization of the blood monocytes and peritoneal macrophages; their lysozyme secretion increases while its synthesis decreases. In other words, the therapeutic application of the transcranial electrical stimulation technique contributed to the disappearance or reduction of 'hot flashes' and the change of these features to the level characteristic of the healthy women. CONCLUSIONS: The data obtained extend our knowledge about the mechanisms underlying the action of TES therapy on the macrophagic cells; moreover, they allow to draw the conclusion that the course of medication with the application this technique not only decreases the intensity of manifestations of the climacteric syndrome but also corrects the function of the immune system during the perimenopause.

[Blood fatty acids in the development and correction of metabolic syndrome]. / Zhirnye kisloty krovi v formirovanii i korrektsii metabolicheskogo sindroma.

AIM: to investigate the composition of plasma fatty acids (FA) and red blood cells and the level of eicosanoids in patients with metabolic syndrome (MS) and to assess whether metabolic disturbances may be corrected during a cycle use of an ω-3 polyunsaturated fatty acid (PUFA). SUBJECTS AND METHODS: Examinations were made in 46 patients, including Group 1 (a control group) of 15 persons without MS components; Group 2 of 31 patients with MS, Group 3 of 16 MS patients who had taken an ω-3 PUFA for 6 months, and Group 4 of 15 MS patients who had received the drug for 12 months. The composition of plasma FA and red blood cells was analyzed on a gas-liquid chromatograph. An enzyme immunoassay was used to measure the serum levels of tumor necrosis factor-α (TNF-α) and eicosanoids (thromboxane B2, 6-keto-prostaglandin F1α, leukotriene B4). A biologically active additive from the king crab (Paralithodes camtschatica) hepatopancreas was used as a source of ω-3 PUFA. RESULTS: Having a higher proportion of linoleic and α-linolenic acids in the plasma, the patients were found to have decreased levels of ω-3 and ω-6 PUFAs (linoleic and α-linolenic, arachidonic, and eicosapentaenoic acids) and a larger proportion of Mead acid and saturated FAs (myristic and stearic acids) in the red blood cells, suggesting that that cellular blood FA transfer was impaired and FAs were absorbed by cells. Their serum samples showed the high levels of leukotriene B4, 6-keto-prostaglandin F1α, and thromboxane A2. The long-term (6- and 12-month) use of ω-3 PUFA from the king crab hepatopancreas had a positive impact in modifying the lipid FA composition of red blood cells and in eliminating deficiencies of physiologically important ω-3 and ω-6 PUFAs in the blood cells. CONCLUSION: The findings suggest that FAs and their metabolites play an important role in the pathogenesis of MS and that dietary ω-3 PUFA should be incorporated into a package of preventive and therapeutic measures for MS.